VolitionRx submits Breakthrough Device request to FDA for Nu.Q sepsis test; H1 revenue exceeds full-year 2022

VOLITIONRX LTD

Submitted Breakthrough Device Designation Request to FDA for Nu.Q technology in sepsis in June 2023.
H1 2023 total revenue $366,000, exceeding full-year 2022 revenue; Nu.Q Vet sales grew five-fold.
Cash $19.7M at June 30, 2023, vs $10.9M at 2022 year-end; raised $17.6M net in June public offering.
Expects $13M in milestone payments from Heska and additional non-dilutive Belgian agency funding.
Centers of Excellence for Nu.Q NETs progressing; first clinical paper submitted for peer review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VOLITIONRX LTD reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the second quarter ended June 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-23-006099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.